Pasar al contenido principal

DESARROLLO Y APLICACION DE PLATAFORMAS DE ALTO RENDIMIENTO BASADA EN FLUORESCENCIA PARA LA SELECCION DE COMPUESTOS ANTIVIRALES FRENTE AL VIRUS DEL NILO OCCIDENTAL Y SARS-COV-2

PID2020-115432RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION UNIVERSITARIA SAN PABLO CEU

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of West Nile virus RNA-dependent RNA polymerase non-nucleoside inhibitors by real-time high throughput fluorescence screening

  • García-Zarandieta, Marta
  • Quesada, Ernesto
  • Martínez-Jiménez, María I.
  • Newnes, Cristina V
  • Fernández-Cabello, Víctor
  • Saez-Alvarez, Yanira
  • Blázquez, Ana B.
  • Escribano-Romero, Estela
  • Saiz Calahorra, Juan Carlos
  • Del Aguila, Carmen
  • Martín-Acebes, M. A.
  • Peréz-Pérez, María-Jesús
  • Agudo, Ruben
8 pág., West Nile virus (WNV) is a re-emergent mosquito-borne RNA virus that causes major outbreaks of encephalitis around the world. However, there is no therapeutic treatment to struggle against WNV, and the current treatment relies on alleviating symptoms. Therefore, due to the threat virus poses to animal and human health, there is an urgent need to come up with fast strategies to identify and assess effective antiviral compounds. A relevant target when developing drugs against RNA viruses is the viral RNA-dependent RNA polymerase (RdRp), responsible for the replication of the viral genome within a host cell. RdRps are key therapeutic targets based on their specificity for RNA and their essential role in the propagation of the infection. We have developed a fluorescence-based method to measure WNV RdRp activity in a fast and reliable real-time way. Interestingly, rilpivirine has shown in our assay inhibition of the WNV RdRp activity with an IC50 value of 3.3 μM and its antiviral activity was confirmed in cell cultures. Furthermore, this method has been extended to build up a high-throughput screening platform to identify WNV polymerase inhibitors. By screening a small chemical library, novel RdRp inhibitors 1-4 have been identified. When their antiviral activity was tested against WNV in cell culture, 4 exhibited an EC50 value of 2.5 μM and a selective index of 12.3. Thus, rilpivirine shows up as an interesting candidate for repurposing against flavivirus. Moreover, the here reported method allows the rapid identification of new WNV RdRp inhibitors., This work was supported by Spanish Ministry of Science and Innovation AEI/10.13039/501100011033 under grant PID2020-115432RB-I00 (to R.A) grant PID2019-105117RR-C21 (to MAM-A); PID2019-105117RR-C22 (to M-JP-P); and from AECSIC under grant PIE-201980E100 (to M-JP-P). This research work was also funded by the European Commission-NextGeneration EU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Development of a luminescence-based method for measuring West Nile Virus MTase activity and its application to screen for antivirals

  • Álvarez-Mínguez, Alejandra
  • Río, Natalia del
  • Blázquez, Ana-Belén
  • Casanova, Elena
  • Orduña, José-María
  • Camarero, Patricia
  • Hurtado-Marcos, Carolina
  • Águila, Carmen del
  • Peréz-Pérez, María-Jesús
  • Martín-Acebes, M. A.
  • Agudo, Rubén
West Nile virus (WNV) is a flavivirus responsible for causing febrile illness and severe neurological diseases, with an increasing impact on human health around the world. However, there is still no adequate therapeutic treatment available to struggle WNV infections. Therefore, there is an urgent need to develop new techniques to accelerate the discovery of drugs against this pathogen. The main protein implicated in the replication of WNV is the non-structural protein 5 (NS5). This multifunctional protein contains methyltransferase (MTase) activity involved in the capping formation at the 5′-end of RNA and the methylation of internal viral RNA residues, both functions being essential for viral processes, such as RNA translation and escape from the innate immune response. We have developed a straightforward luminescence-based assay to monitor the MTase activity of the WNV NS5 protein with potential for high-throughput screening. We have validated this method as a sensitive and suitable assay for the identification of WNV MTase inhibitors assessing the inhibitory effect of the broad MTase inhibitor sinefungin, a natural nucleoside analog of the universal methyl donor S-adenosyl methionine (SAM). The screening of a small series of purine derivatives identified an adenosine derivative as a dose-dependent inhibitor of the MTase activity. The antiviral efficacy of this compound was further confirmed in WNV infections, displaying a measurable antiviral effect. This result supports the utility of this novel method for the screening of inhibitors against WNV MTase activity, which can be of special relevance to the discovery and development of therapeutics against WNV., This work was supported by Ministerio de Ciencia e Innovación y Universidades, Agencia Estatal de Investigación MICIU/AEI/10.13039/ 501,100,011,033 under grants PID2020–115432RB-I00 (to RA), PID2019–105117RR-C21 (to MAM-A), PID2019–105117RR-C22 (to MJP-P), PID2022–137372OR-C21 (to MAM-A) and PID2022–137372ORC21 (to M-JP-P), by the European Commission—Next Generation EU through CSIC’s Global Health Platform (PTI Salud Global) (to M-JP-P and MAM-A) and by CSIC-PIE202380E090 (to M-JP-P). AA-M. is the recipient of an FPU-predoctoral fellowship FPU22/03025 granted by MICIU/AEI/10.13039/501,100,011,033 and the FSE+. The funders did not participate in the study design, data collection and interpretation, or the decision to submit the work for publication., Peer reviewed